ClinicalTrials.gg
CompletedNCT05740475Updated Dec 9, 2025

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects

A Phase 1 interventional study of 9MW3811 injection and Placebo in Pulmonary Fibrosis and Tumor, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 26 studies in Pulmonary Fibrosis with a site in Australia — 5 open to participants now, 9 under way, 3 of them phase 3. Pulmonary Fibrosis · Australia.

Enrollment
20th of 24
32 · median 206
Started
2023
with 4 others
Phase 1
4 of 26
none open now
Registered
14th of 26
by date

Among the 26 studies in Pulmonary Fibrosis with a site in Australia, this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2023, is one of 4 in phase 1, and was the 14th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

5 of the 26 studies in Pulmonary Fibrosis with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pulmonary Fibrosis with a site in Australia, or all of them as a file.
02

Study summary

This is a first-in-human, single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety and tolerability of 9MW3811 in healthy adult participants.

Read the detailed description

The single ascending dose study will comprise 4 dose cohorts of 8 healthy participants each. In each cohort, participants will be randomized to receive 9MW3811 or placebo by 6:2.

03

Conditions studied

  • Pulmonary Fibrosis
  • Tumor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants between 18 and 55 years of age, inclusive.
  2. Male body weight ≥50.0 kg, or female body weight ≥45.0 kg, and (BMI) between 18.0 and 30.0 kg/m2, inclusive.
  3. In good health determined by the investigator based on a medical evaluation, including a detailed medical and surgical history, as well as a complete physical examination including vital signs, 12-lead , laboratory evaluations.

Exclusion criteria

Exclusion Criteria:

  1. histories determined by the investigator of cardiovascular, hepatic, renal, gastrointestinal, neurological, respiratory, hematological, endocrinological, immunological, metabolic, and musculoskeletal abnormalities.
  2. Having any history of an allergy to biological agents or any components of study drug; those who have a history of allergies and judged by the investigator to be ineligible for enrolment.
  3. Use of any prescription medication 14 days prior to dosing or over-the-counter medication, vitamins, and/or herbal medicines 7 days prior to dosing (Excluding oral , occasional paracetamol, ibuprofen and standard dose of multivitamins at the discretion of the PI or designee)
  4. Participants who have been vaccinated within 4 weeks prior to screening or who are scheduled to be vaccinated during the study
  5. Participants who received except for previous use of inhaled or nasal 4 weeks earlier before administration or any oral corticosteroids 8 weeks earlier before administration, and who had received a single dose of monoclonal antibodies for any reason within 1 year prior to screening
  6. Participants with one or more clinically significant positive test results of surface antigen (HBsAg), virus (HCV) antibody or (HIV) antibody
  7. History of drug abuse including narcotic and psychiatric drugs within 6 months prior to screening or a positive drug abuse test result at baseline (Morphine, Methamphetamine, Tetrahydrocannabinol acid, Cocaine)
  8. Participants with a positive SARS-CoV-2 test prior to admission (polymerase chain reaction (PCR) and/or rapid antigen testing (RAT), per site policy and PI discretion)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    9MW3811 injection

    single dose escalation for experimental drug

    Drug: 9MW3811 injection

  • Placebo comparator
    placebo

    matching placebo administration for control

    Drug: Placebo

Interventions

  • Single dose intravenously infused on day 1

  • DrugPlacebo

    Single dose of matching placebo intravenously infused on day 1

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) as assessed by CTCAE v5.0

    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: up to Day113

  2. Number of participants with abnormal clinically significant results from physical examination

    The physical examinations will include examination of the following: head, eyes, ears, nose and throat, neck (including thyroid \& nodes), cardiovascular system, dermatological system, musculoskeletal system, respiratory system, gastrointestinal system, neurological system and renal system.

    Time frame: up to Day113

  3. Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parameters

    The examination indicators include heart rate, PR, QRS, uncorrected QT, and QTcF \[corrected by Fridericia formula, QTcF = QT/(RR\^0.33), RR is the standardized heart rate value, which is obtained by dividing 60 by the heart rate\].

    Time frame: up to Day113

  4. Number of participants with abnormally clinical vital signs

    Vital signs measurements will include pulse rate, respiration rate, blood pressure (systolic and diastolic blood pressure) and body temperature.

    Time frame: up to Day113

  5. Number of participants with abnormal clinically significant clinical laboratory results

    Clinical laboratory tests include hematology, urinalysis, blood chemistry, coagulation function.

    Time frame: up to Day113

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in healthy adult participants.

    Time frame: up to Day 113

  2. Time to reach Cmax (Tmax)

    To determine the PK of 9MW3811 following single ascending intravenous doses in healthy adult participants.

    Time frame: up to Day 113

  3. Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t)

    To determine the PK of 9MW3811 following single ascending intravenous doses in healthy adult participants.

    Time frame: up to Day 113

  4. Terminal elimination half-life (t1/2)

    To determine the PK of 9MW3811 following single ascending intravenous doses in healthy adult participants.

    Time frame: up to Day 113

  5. AUC from time 0 extrapolated to infinity (AUC0-inf)

    To determine the PK of 9MW3811 following single ascending intravenous doses in healthy adult participants.

    Time frame: up to Day 113

  6. Terminal elimination rate constant (λz)

    To determine the PK of 9MW3811 following single ascending intravenous doses in healthy adult participants.

    Time frame: up to Day 113

  7. Apparent clearance (CL)

    To determine the PK of 9MW3811 following single ascending intravenous doses in healthy adult participants.

    Time frame: up to Day 113

  8. Volume of distribution (Vz)

    To determine the PK of 9MW3811 following single ascending intravenous doses in healthy adult participants.

    Time frame: up to Day 113

  9. Incidence of antidrug antibodies (ADA) at specified timepoints relative to baseline

    To determine the immunogenicity of 9MW3811.

    Time frame: up to Day 113

Other outcomes

  1. Serum interleukin-11 (IL-11) level after administration at specified timepoints relative to baseline

    To explore the pharmacodynamics (PD) of 9MW3811.

    Time frame: up to Day 113

07

Study locations

1 site
  • Scientia Clinical Research
    Randwick, New South Wales, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Sep 2023, 5 months.

Of 20 phase 1 interventional studies under Pulmonary Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 55. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2023
First posted
Feb 23, 2023
StartActual
Mar 20, 2023
Primary completionActual
Sep 14, 2023
CompletionActual
Jan 6, 2024
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05740475
Responsible party
Sponsor
First posted
Feb 23, 2023
Start date
Mar 20, 2023
Primary completion
Sep 14, 2023
Completion
Jan 6, 2024
Last update
Dec 9, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-IL-11 Monoclonal Antibody 9MW3811

Start the discussion